A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors

PURPOSE: This phase I study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics, and antitumor activity of the Aurora B kinase inhibitor BI 811283 in patients with advanced solid tumors. METHODS: BI 811283 was administered via 24-h infusion on Days 1 and 15 of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mross, Klaus, Richly, Heike, Frost, Annette, Scharr, Dirk, Nokay, Bahar, Graeser, Ralph, Lee, Chooi, Hilbert, James, Goeldner, Rainer-George, Fietz, Oliver, Scheulen, Max E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080318/
https://www.ncbi.nlm.nih.gov/pubmed/27349901
http://dx.doi.org/10.1007/s00280-016-3095-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080318/
https://www.ncbi.nlm.nih.gov/pubmed/27349901
http://dx.doi.org/10.1007/s00280-016-3095-6

Ejemplares similares